NASDAQ:COLL - Collegium Pharmaceutical Stock Price, Forecast & News

Collegium Pharmaceutical trades on the NASDAQ under the ticker symbol "COLL."

Collegium Pharmaceutical Inc (NASDAQ:COLL) released its quarterly earnings results on Wednesday, November, 6th. The specialty pharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.15) by $0.03. The specialty pharmaceutical company earned $72.94 million during the quarter, compared to the consensus estimate of $74.32 million. Collegium Pharmaceutical had a negative net margin of 3.86% and a negative return on equity of 13.14%. The business's revenue for the quarter was up 3.9% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.50) earnings per share. View Collegium Pharmaceutical's Earnings History.

Collegium Pharmaceutical is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Collegium Pharmaceutical.

6 equities research analysts have issued 12 month price targets for Collegium Pharmaceutical's shares. Their forecasts range from $22.00 to $36.00. On average, they anticipate Collegium Pharmaceutical's share price to reach $29.33 in the next year. This suggests a possible upside of 40.0% from the stock's current price. View Analyst Price Targets for Collegium Pharmaceutical.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Collegium Pharmaceutical in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Collegium Pharmaceutical.

Headlines about COLL stock have trended extremely negative recently, InfoTrie Sentiment reports. The research group identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Collegium Pharmaceutical earned a coverage optimism score of -4.5 on InfoTrie's scale. They also gave media coverage about the specialty pharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next several days. View News Stories for Collegium Pharmaceutical.

Collegium Pharmaceutical saw a increase in short interest in the month of January. As of January 15th, there was short interest totalling 2,040,000 shares, an increase of 22.9% from the December 31st total of 1,660,000 shares. Based on an average daily volume of 442,100 shares, the short-interest ratio is currently 4.6 days. Currently, 7.0% of the shares of the company are short sold. View Collegium Pharmaceutical's Current Options Chain.

Some companies that are related to Collegium Pharmaceutical include Uniqure (QURE), Epizyme (EPZM), ArQule (ARQL), Zogenix (ZGNX), ChemoCentryx (CCXI), Amicus Therapeutics (FOLD), Karuna Therapeutics (KRTX), Arena Pharmaceuticals (ARNA), Ra Pharmaceuticals (RARX), Synthorx (THOR), Turning Point Therapeutics (TPTX), Aurinia Pharmaceuticals (AUPH), Heron Therapeutics (HRTX), Prestige Consumer Healthcare (PBH) and Eidos Therapeutics (EIDX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Collegium Pharmaceutical investors own include GALAPAGOS NV/S (GLPG), AbbVie (ABBV), NVIDIA (NVDA), Advanced Micro Devices (AMD), Celgene (CELG), Bausch Health Companies (BHC), Canopy Growth (CGC), GW Pharmaceuticals PLC- (GWPH), Intercept Pharmaceuticals (ICPT) and Ocular Therapeutix (OCUL).

(COLL) raised $75 million in an initial public offering on Thursday, May 7th 2015. The company issued 5,800,000 shares at $12.00-$14.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers.

Collegium Pharmaceutical's stock is owned by a number of of retail and institutional investors. Top institutional investors include Strs Ohio (0.11%) and Campbell & CO Investment Adviser LLC (0.04%). Company insiders that own Collegium Pharmaceutical stock include Alison B Fleming, David Hirsch, Joseph Ciaffoni, Michael Thomas Heffernan, Paul Brannelly and Scott Dreyer. View Institutional Ownership Trends for Collegium Pharmaceutical.

COLL stock was sold by a variety of institutional investors in the last quarter, including Strs Ohio. Company insiders that have sold Collegium Pharmaceutical company stock in the last year include David Hirsch, Joseph Ciaffoni, Michael Thomas Heffernan and Scott Dreyer. View Insider Buying and Selling for Collegium Pharmaceutical.

COLL stock was purchased by a variety of institutional investors in the last quarter, including Campbell & CO Investment Adviser LLC. View Insider Buying and Selling for Collegium Pharmaceutical.

Shares of COLL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of COLL stock can currently be purchased for approximately $20.95.

Collegium Pharmaceutical has a market capitalization of $702.45 million and generates $280.41 million in revenue each year. The specialty pharmaceutical company earns $-39,130,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis. Collegium Pharmaceutical employs 266 workers across the globe.View Additional Information About Collegium Pharmaceutical.

The official website for Collegium Pharmaceutical is http://www.collegiumpharma.com/.

Collegium Pharmaceutical's mailing address is 100 Technology Center Drive, Stoughton MA, 02072. The specialty pharmaceutical company can be reached via phone at 781-713-3699.